Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

63850 1504871583HCLSReviewHongKongSeptember2017.pdf
Energy Boardroom

AstraZeneca unveils rosy forecast to persuade investors it's better off alone

06.05.2014 / Fierce Pharma

Now, it's AstraZeneca's turn to tick off all the reasons why it shouldn't sell to Pfizer. Between new plans for existing products and its prospects for new ones, AstraZeneca says it will boost sales to $45 billion by 2023–about $20 billion higher than they are now.

LATEST ISSUE

DOWNLOAD

Most Read

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: